Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept plus Ozurdex versus conbercept alone for diabetic macular edema
ChiCTR2200059909Phase 4Recruiting
- Sponsor
- Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
- Start
- May 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept and ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong. Primary endpoints: Best-corrected visual acuity and Central macular thickness. Started May 2022; status: recruiting.
02
Drugs
conberceptozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2200059909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059909.